Krystal Biotech (NASDAQ:KRYS) Stock Rating Reaffirmed by HC Wainwright

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $200.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 23.43% from the stock’s previous close.

Several other research firms have also commented on KRYS. Stifel Nicolaus reaffirmed a “buy” rating and set a $204.00 target price (up from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. Guggenheim boosted their price objective on Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Citigroup boosted their price objective on Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Finally, William Blair reiterated an “outperform” rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $171.00.

Krystal Biotech Stock Up 3.0 %

Shares of Krystal Biotech stock opened at $162.04 on Monday. The firm has a market cap of $4.62 billion, a P/E ratio of 2,025.75 and a beta of 0.85. Krystal Biotech has a fifty-two week low of $82.09 and a fifty-two week high of $189.97. The business has a 50-day moving average price of $161.64 and a 200 day moving average price of $130.95.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.82. The firm had revenue of $42.14 million during the quarter, compared to the consensus estimate of $27.43 million. During the same period in the prior year, the firm earned ($1.25) earnings per share. As a group, equities research analysts anticipate that Krystal Biotech will post 1.89 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 8,087 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $136.91, for a total transaction of $1,107,191.17. Following the sale, the chief accounting officer now directly owns 12,556 shares of the company’s stock, valued at approximately $1,719,041.96. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CAO Kathryn Romano sold 8,087 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $136.91, for a total value of $1,107,191.17. Following the transaction, the chief accounting officer now directly owns 12,556 shares of the company’s stock, valued at $1,719,041.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the transaction, the insider now directly owns 1,550,882 shares in the company, valued at $265,138,786.72. The disclosure for this sale can be found here. Insiders have sold a total of 38,087 shares of company stock valued at $6,210,591 in the last three months. 14.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Krystal Biotech

Hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. increased its stake in shares of Krystal Biotech by 111.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 718 shares of the company’s stock worth $83,000 after purchasing an additional 379 shares during the period. Quest Partners LLC bought a new position in shares of Krystal Biotech in the fourth quarter worth about $127,000. Pier 88 Investment Partners LLC bought a new position in shares of Krystal Biotech in the fourth quarter worth about $145,000. Fox Run Management L.L.C. bought a new position in shares of Krystal Biotech in the third quarter worth about $219,000. Finally, Capstone Investment Advisors LLC bought a new position in shares of Krystal Biotech in the fourth quarter worth about $303,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).